Xuanzhu Bio, Trinomab, IASO Bio, Zhongsheng Ruichuang, and Changtai Pharma Included in China's 2025 Dual Medical Insurance Directories

Dec 08, 2025 16:13 CST Updated 16:13

XZenith Biopharm

Researcher and Developer of New Molecular Entity Drugs

Trinomab

Developer of Natural Fully Human Monoclonal Antibody New Drugs

IASO Biotechnology

Cancer Treatment New Drug Developer

On December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the new edition of the "National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug Catalog" and the "Commercial Health Insurance Innovative Drug Catalog" (2025).

This adjustment to the medical insurance drug list is the 8th since the establishment of the National Medical Insurance Administration, and the new version of the directory will be officially implemented nationwide in China starting from January 1st of next year. This effort has been successfully completed.114 New Drugs AddedAmong them, 50 are Class I innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024.

Moreover, for the first time in this adjustment of the medical insurance catalog, a commercial insurance innovative drug list has been simultaneously introduced, forming a dual-track system of basic medical insurance and commercial health insurance to collaboratively ensure innovative drugs. This will greatly benefit the further development and growth of China's self-developed innovative drug industry and will also further enhance the accessibility of Class 1 innovative drugs, benefiting patients to a greater extent.。

The first edition of the Commercial Insurance Innovative Drug List focuses on including innovative drugs with high levels of innovation, significant clinical value, and substantial patient benefits that go beyond the scope of basic medical insurance. It recommends reference use by multi-level medical security systems such as commercial health insurance and medical mutual aid. This time, a total of 19 drugs were included, including tumor treatment drugs like CAR-T, as well as others.Neuroblastoma, Gaucher's disease and other rare disease treatment drugs, as well as those with higher social attentionAlzheimer's DiseaseTherapeutic drugs, etc.

ThisPortfolio Companies of Efung CapitalXZenith Biopharm【Piroxel Tablets】、Trinomab [Stedutamab Injection】, IASO Bio 【IKiorlance Injection】、raynovent【Angladrine Tablets】、Pharmamax Pharmaceuticals, Ltd.【Olanzapine and Fluoxetine Capsules】Selected.In the future,Yifeng Capital willContinuously focus on life science companies driven by breakthrough technologies and clinical value, deepen efforts in new drug development, biotechnology, and high-end medical products, jointly promote the high-quality development of China's pharmaceutical industry, and contribute capital and industrial synergy to the construction of Healthy China.

National Medical Insurance Drug Catalog

轩竹生物、泰诺麦博、驯鹿生物、众生睿创、长泰药业入选2025国家医保商保“双目录” | 锋投动态

Commercial Insurance Innovative Drug List